title: Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials.
abstract: Pulmonary disease is the leading cause of morbidity and mortality in patients with systemic sclerosis (SSc). Recent well-designed trials in SSc-associated interstitial lung disease (SSc-ILD) have provided important insights regarding outcome measures and trial design. Recent investigations into the pathogenesis of SSc-ILD have led to a renewed interest in assessing targeted therapies in SSc-ILD. With this in mind, we propose recommendations for the design of future SSc-ILD studies in this review.
authors.affiliation: Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA. dkhanna@mednet.ucla.edu
authors.forename: Dinesh
authors.initials: D
authors.lastname: Khanna
authors.forename: Kevin K
authors.initials: KK
authors.lastname: Brown
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Clements
authors.forename: Robert
authors.initials: R
authors.lastname: Elashoff
authors.forename: Daniel E
authors.initials: DE
authors.lastname: Furst
authors.forename: Jonathan
authors.initials: J
authors.lastname: Goldin
authors.forename: James R
authors.initials: JR
authors.lastname: Seibold
authors.forename: Richard M
authors.initials: RM
authors.lastname: Silver
authors.forename: Donald P
authors.initials: DP
authors.lastname: Tashkin
authors.forename: Athol U
authors.initials: AU
authors.lastname: Wells
mesh_terms: D023381:Endpoint Determination; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D012107:Research Design; D012595:Scleroderma, Systemic / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014797:Vital Capacity